Monoclonal antibodies in oncology therapeutics: present and future indications

Bibliography

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Sainsbury JR, Malcolm AJ, Appleton DR. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985;38(11):1225-8
   PubMed Web of Science ®Google Scholar
• Saeki T, Salomon DS, Johnson GR. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995;25(6):240-9
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006;366(1):2-16
   Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1(11):1311-18
   PubMed Web of Science ®Google Scholar
• Wu X, Fan Z, Masui H, Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95(4):1897-905
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Masui H, Pandiella A. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85(16):1327-33
   PubMed Web of Science ®Google Scholar
• Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637-42
   PubMed Web of Science ®Google Scholar
• Klapper LN, Vaisman N, Hurwitz E, A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14(17):2099-109
   PubMed Web of Science ®Google Scholar
• Lane HA, Beuvink I, Motoyama AB, ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20(9):3210-23
   PubMed Web of Science ®Google Scholar
• Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006;29(4):388-97
   PubMed Web of Science ®Google Scholar
• Dall'Ozzo S, Tartas S, Paintaud G, Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64(13):4664-9
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9(16 Pt 1):5866-73
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6(4):443-6
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90(3):1109-14
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Zarate R, Bandres E. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 2012;48(12):1774-80
   PubMed Web of Science ®Google Scholar
• Choi BD, Cai M, Bigner DD. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011;11(7):843-53
   PubMed Web of Science ®Google Scholar
• Topp M, Goekbuget N, Zugmaier G. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL [abstract # 6500]. ASCO; 2012
   Google Scholar
• Topp MS, Kufer P, Gokbuget N. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8
   PubMed Web of Science ®Google Scholar
• Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998 Mar;50(1):59-87
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-7
   PubMed Web of Science ®Google Scholar
• Golay J, Cittera E, Di Gaetano N, The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006;91(2):176-83
   PubMed Web of Science ®Google Scholar
• Zent CS, Chen JB, Kurten RC. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004;28(5):495-507
   PubMed Web of Science ®Google Scholar
• Treon SP, Mitsiades C, Mitsiades N, Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24(3):263-71
   Web of Science ®Google Scholar
• Van der Kolk LE, Grillo-Lopez AJ, Baars JW, Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807-11
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56(17):4032-9
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7
   PubMed Web of Science ®Google Scholar
• Hodge DR, Peng B, Cherry JC. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005;65:4673-82
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85(4):863-72
   PubMed Web of Science ®Google Scholar
• Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9(13):4653-65
   PubMed Web of Science ®Google Scholar
• Rossi JF, Negrier S, James ND. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103(8):1154-62
   PubMed Web of Science ®Google Scholar
• Coward J, Kulbe H, Chakravarty P. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17(18):6083-96
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Magarotto V, Kuhn DJ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011;152:579-92
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68(22):9280-90
   PubMed Web of Science ®Google Scholar
• Pasquetto MV, Vecchia L, Covini D. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011;34(9):611-28
   PubMed Web of Science ®Google Scholar
• Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20(8):1131-49
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67(6):2643-8
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-705
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Clin Oncol 2002;20(3):719-26
   Web of Science ®Google Scholar
• Burstein HJ, Keshaviah A, Baron AD. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110(5):965-72
   PubMed Web of Science ®Google Scholar
• Robert N, Leyland-Jones B, Asmar L. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24(18):2786-92
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Cortes J. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305(5):487-94
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97(1):101-6
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23(18):4117-26
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24(19):3121-7
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19(8):2153-64
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M. Early results of a chemoimmunotherapy regimen of fludarabine, Cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105(1):49-53
   PubMed Web of Science ®Google Scholar
• Abdulla NE, Ninan MJ, Markowitz AB. Rituximab: current status as therapy for malignant and benign hematologic disorders. BioDrugs 2012;26(2):71-82
   PubMed Web of Science ®Google Scholar
• Rai KR, Freter CE, Mercier RJ. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20(18):3891-7
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99(10):3554-61
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27(24):3994-4001
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106
   PubMed Web of Science ®Google Scholar
• O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13(1):16-24
   PubMed Web of Science ®Google Scholar
• Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002;1:339-53
   PubMed Web of Science ®Google Scholar
• Jones RA, Campbell CI, Gunther EJ, Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636-44
   PubMed Web of Science ®Google Scholar
• Haluska P, Shaw HM, Batzel GN. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13(19):5834-40
   PubMed Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27(15):2516-22
   PubMed Web of Science ®Google Scholar
• Schmitz S, Kaminsky-Forrett MC, Henry S. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 2012;23(8):2153-61
   PubMed Web of Science ®Google Scholar
• Malempati S, Weigel B, Ingle AM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30(3):256-62
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sarantopoulos J, Patnaik A. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27(34):5800-7
   PubMed Web of Science ®Google Scholar
• Atzori F, Tabernero J, Cervantes A. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011;17(19):6304-12
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Kuhn DJ. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Fayad L, Voorhees P. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28(23):3701-8
   PubMed Web of Science ®Google Scholar
• Dorff TB, Goldman B, Pinski JK. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16(11):3028-34
   PubMed Web of Science ®Google Scholar
• Gille H, Kowalski J, Li B. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276(5):3222-30
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56(5):739-45
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381-5
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14(10):3044-51
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Bakan CE, Mishra A. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286-94
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Najjar YG, Raulfs EC. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41(10):2977-86
   PubMed Web of Science ®Google Scholar
• Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol 2011;5:45-53
   PubMedGoogle Scholar
• Wierda WG, Padmanabhan S, Chan GW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011;118(19):5126-9
   PubMed Web of Science ®Google Scholar
• Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12(3):343-51
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51(5):747-55
   PubMed Web of Science ®Google Scholar
• Burris HA III, Rugo HS, Vukelja SJ. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-405
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK. Results of a Pivotal Phase 2 Study of Brentuximab vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2010;116:283
   Google Scholar
• Advani A, Coiffier B, Czuczman MS. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28(12):2085-93
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13(4):403-11
   PubMed Web of Science ®Google Scholar
• A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer. NCT01283373
   Google Scholar
• Gudas M, An Z, Morrison RK, Morrison KJ. ASG-5ME: a novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers [abstract # 230]. ASCO; 2010
   Google Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52(12):3402-8
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172(5):3280-8
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186(3):1840-8
   PubMed Web of Science ®Google Scholar
• Alinari L, Yu B, Christian BA, Yan F. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011;117(17):4530-41
   PubMed Web of Science ®Google Scholar
• Lewis TS, McCormick RS, Stone IJ. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 2011;25(6):1007-16
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012;
   PubMed Web of Science ®Google Scholar
• Sutherland MK, Yu C, Lewis TS. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 2009;1(5):481-90
   PubMed Web of Science ®Google Scholar